Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | SVP, Chief Financial Officer | September 03, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,839 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 453 · Balance 13,839 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 4, 2026 20:25 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 453 | $3.04 | $1,375.85 |
DisclosureSEC source: 0002063082-26-000006 · wk-form4_1788553522.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,839 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 678 | $2.58 | $1,749.24 |
DisclosureSEC source: 0002063082-26-000003 · wk-form4_1785960474.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,292 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 1, 2026. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 464 | $2.70 | $1,253.26 |
DisclosureSEC source: 0001650664-26-000057 · wk-form4_1780691609.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,970 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7049. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 20:35 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 292,856 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001650664-26-000022 · wk-form4_1773693348.xml · derivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,856 Underlying: Common Stock · 292,856 shares Expires 2036-03-11 F1 · derivative.exercise_date: This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:49 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 474 | $2.02 | $957.48 |
DisclosureSEC source: 0001650664-26-000007 · wk-form4_1772660958.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,434 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:38 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 461 | $2.15 | $992.58 |
DisclosureSEC source: 0001650664-25-000161 · wk-form4_1764884284.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,908 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 20:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 458 | $2.60 | $1,189.01 |
DisclosureSEC source: 0001650664-25-000142 · wk-form4_1757017244.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,369 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:28 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 679 | $2.58 | $1,751.82 |
DisclosureSEC source: 0001650664-25-000118 · wk-form4_1754684878.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,827 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 6, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 22:39 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 446 | $1.72 | $768.90 |
DisclosureSEC source: 0001650664-25-000093 · wk-form4_1749076755.xml · nonDerivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,506 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person F2 · price: This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7522. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 20:29 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 34,672 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001650664-25-000052 · wk-form4_1744144175.xml · derivative · entry 1 Parison Amy · CIK 0002063082 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,672 Underlying: Common Stock · 34,672 shares Expires 2035-04-07 F1 · derivative.exercise_date: This option was granted on April 8, 2025 and is scheduled to vest over four years, with 25% of the shares to vest on April 8, 2026 and the remaining 75% of the shares scheduled to vest in equal monthly monthly installments thereafter through April 8, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.